Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Acurx Pharmaceuticals Inc (NQ: ACXP )

0.9290 +0.0440 (+4.97%)
Streaming Delayed Price Updated: 3:59 PM EST, Dec 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Acurx Pharmaceuticals Inc

< Previous 1 2 Next >
CEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, Pipeline, and Potential Near-Term Catalysts
New York, New York--(Newsfile Corp. - September 13, 2021) - Acurx Pharmaceuticals (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company developing... 
Via Newsfile
Topics Death Derivatives Initial Public Offering
Exposures Death Derivatives Intellectual Property
Acurx Pharmaceutical’s Reaches Another Milestone With Russell Microcap Inclusion; Shares Extend August Gains (NASDAQ: ACXP)
Via AB Newswire
Acurx Pharmaceutical’s Is Disruptive To The Antibiotics Landscape- That’s Great News For Patients With Gram-Positive Infections (NASDAQ: ACXP)
Via AB Newswire
Acurx Pharmaceuticals Plan To Change The Antibiotics Landscape Is Simple- Make Better Drugs That Target Gram-Positive Infections
Via AB Newswire
Acurx Pharmaceutical’s On Pace To Change The Antibiotics Landscape; Trial Data Shows 100% Sustained Clinical Cure In Treating Gram-Positive Infection CDI
Via AB Newswire
Drug Makers Overseas Are Gaining A Competitive Advantage In The Antibiotics R&D Market; Acurx Pharmaceuticals Ibezapolstat Program Is Helping Level The Field (NASDAQ: ACXP)
Via AB Newswire
Gram Positive Bacterial Infections Can Be Fatal; Acurx Pharmaceuticals Is One Of The Few Working To Change The Treatment Landscape (NASDAQ: ACXP)
Via AB Newswire
Acurx Pharmaceuticals Leverages IPO Capital To Develop Most Significant Advance To Antibiotics In More Than 40 Years (NASDAQ: ACXP)
Via AB Newswire
Topics Initial Public Offering
Exposures Securities Market
Acurx Pharmaceuticals On Pace To Deliver The Most Important Upgrade To Antibiotics Since The 1980s (NASDAQ: ACXP)
Via AB Newswire
Topics Initial Public Offering
Exposures Securities Market
Post-IPO Acurx Pharmaceuticals Expects To Deliver The First Meaningful Change To Antibiotics Market Since 1980s (NASDAQ: ACXP)
Via AB Newswire
Topics Initial Public Offering
Exposures Securities Market
Acurx Pharmaceuticals Shares 15% Higher Post-IPO; On Track To Bring A New Class Of Effective Antibiotics To Market (NASDAQ: ACXP)
Via AB Newswire
Topics Initial Public Offering
Exposures Securities Market
Acurx Pharmaceuticals Shares Surge 31% Following Its Debut Public Offering; Low Share Count And $15 Million Presents A Compelling Investment Opportunity
Via AB Newswire
Topics Initial Public Offering
Exposures Securities Market
Acurx Pharmaceuticals Draws Interest After Morning IPO; Could Deliver First Class Of New Antibiotics Since The 1980’s (Nasdaq: ACXP)
Via AB Newswire
Topics Initial Public Offering
Exposures Securities Market
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.